Company Overview - Dentsply Sirona is led by CEO Dan Scavilla, who joined the company five months ago after a successful tenure at Globus Medical, where he helped grow revenue from $300 million to $3 billion [2] - Scavilla has extensive experience in the healthcare sector, having spent 28 years at Johnson & Johnson, which provided him with insights into various business models applicable to the current healthcare environment [3] Strategic Focus - The company emphasizes the strength of its brands and customer loyalty, which are seen as key assets in shaping the future of dentistry and connected dentistry [4] - Dentsply Sirona has an integrated portfolio that positions it well to influence advancements in the dental industry [4]

Dentsply Sirona FY Conference Summary Company Overview - **Company**: Dentsply Sirona (NasdaqGS: XRAY) - **Industry**: Dental Technology - **Market Presence**: Operates in over 100 countries, engaging approximately 400,000 practitioners annually through training programs [3][2] Key Points and Arguments Market Position and Growth Potential - **Total Addressable Market (TAM)**: $33 billion annually, with a growth rate of 3%-4% [4] - **Product Innovation**: Launched over 50 new products in the past four years, maintaining leadership in single-visit dentistry with the CEREC mill system [3] - **Brand Strength**: Strong brand loyalty among dentists, with a focus on integrated portfolio offerings [2] Challenges Faced by Dentists - **Patient Treatment Acceptance**: 54% of patients decline treatments offered by dentists, impacting revenue [5] - **Operational Constraints**: 36% of dentists face efficiency issues, limiting patient throughput [6] - **Cost Barriers**: Nearly 80% of dentists view costs as a significant barrier to adopting digital dentistry [6] Strategic Initiatives for Growth - **Return-to-Growth Action Plans**: Focus on customer-centric strategies, enhancing engagement with dentists, and increasing R&D investment [12][16] - **Investment in R&D**: Current spending at 4% ($150 million) of revenue, with plans to increase to 6% over the next 24 months [50][16] - **Unified Commercial Functions**: Creation of a Chief Commercial Officer role to streamline operations and enhance market penetration [18] Focus Areas for Investment - **Key Segments**: Prioritizing investment in implantology and orthodontics, where the company currently underindexes [11][51] - **DS Core Platform**: Aiming to enhance the DS Core platform to provide a comprehensive ecosystem for dentists [8][11] Financial Strategies - **Cash Flow Improvement**: Plans to reduce inventory by 20% and enhance free cash flow to support growth initiatives [26][27] - **Tax Strategy**: Aiming for a tax rate of 26%-28% in 2026, with a goal to lower it further through improved structures [56] Organizational Changes - **Leadership Appointments**: New Chief Commercial Officer and a focus on vertical alignment of sales teams to enhance market focus [29][41] - **Growth and Value Committee**: Established to oversee strategic moves, including capital allocation and potential acquisitions [32][40] Additional Important Insights - **AI Strategy**: Implementation of AI to improve operational efficiencies and decision-making processes [21] - **Market Trends**: Acknowledgment of macroeconomic factors such as high interest rates affecting capital purchases, but emphasis on internal improvements as the primary focus for growth [45][46] - **Wellspect Business**: Retained as a significant cash flow contributor, with plans for independent operation and potential future divestiture if necessary [48] Conclusion Dentsply Sirona is positioned in a growing dental technology market with a strong brand and innovative product offerings. The company is implementing a comprehensive return-to-growth strategy focused on enhancing customer engagement, increasing R&D investment, and streamlining operations to improve financial performance and market share.

J.P. Morgan Healthcare Conference Dan Scavilla President and Chief Executive Officer January 13, 2026 Forward-Looking Statements and Associated Risks This presentation contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the Company's return-to-growth action plan described in this presentation and statements and projections regarding the Company's use of technolog ...

Core Insights - Dentsply Sirona and Benco Dental are expanding their partnership to include a full range of dental technology solutions, enhancing access to an integrated ecosystem for connected dentistry [1][2][3] Group 1: Partnership Details - Benco Dental will offer Dentsply Sirona's comprehensive suite of connected technology solutions, including the CEREC system and intraoral scanners like Primescan [2][3] - The collaboration aims to simplify digital adoption and improve efficiency in dental practices, leveraging Benco Dental's customer service and Dentsply Sirona's technology [3][6] Group 2: Customer Support and Experience - Benco Dental will create dedicated Dentsply Sirona experiences in its CenterPoint showrooms, allowing dental professionals to explore and test the latest technologies [7][9] - The showrooms will feature an interior design studio to optimize Dentsply Sirona installations, enhancing the customer experience [8][9] Group 3: Company Backgrounds - Dentsply Sirona is the largest diversified manufacturer of professional dental products, with a strong focus on innovation and customer-centric solutions [10] - Benco Dental is a national dental distributor with a century-long history, committed to supporting dental providers and driving innovation in the industry [11]

Core Insights - Dentsply Sirona has appointed Donald Zurbay to its Board of Directors, effective January 10, 2026, to enhance its governance and support its Return-to-Growth Action Plan [1][3][4] Group 1: Appointment of Donald Zurbay - Mr. Zurbay brings over 30 years of experience in finance and accounting, with significant leadership roles in the dental and healthcare industries, including his recent position as President and CEO of Patterson Companies [2][7] - His familiarity with Dentsply Sirona stems from a longstanding partnership between Patterson and the Company, which will aid in strategic decision-making [2][3] - The Board's Corporate Governance and Nominating Committee led Mr. Zurbay's appointment, increasing the Board size from 10 to 11 members [3] Group 2: Growth and Value Creation Committee - A new four-member Growth and Value Creation Committee has been established, co-chaired by the Board Chairman and the Company's President & CEO, to oversee the Return-to-Growth action plan [5][6] - The Board is committed to actively engaging with management to monitor progress, evaluate growth opportunities, and ensure alignment with strategic priorities [6] - This governance structure aims to facilitate timely decision-making and disciplined oversight, enhancing the execution of the growth strategy [6] Group 3: Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, with a history of over a century in the dental industry [8] - The Company offers a comprehensive range of dental and oral health products, as well as consumable medical devices, under a strong portfolio of world-class brands [8] - Dentsply Sirona is headquartered in Charlotte, North Carolina, and its shares are listed on Nasdaq under the symbol XRAY [8]

Core Insights - Dentsply Sirona has appointed Mark R. Bezjak as Group Vice President for the Americas Regional Commercial Organization, effective January 28, 2026, to enhance commercial execution and accelerate growth across the Americas [1][2]. Group 1: Appointment and Role - The appointment of Mark R. Bezjak is aimed at strengthening Dentsply Sirona's commercial execution and deepening customer relationships [2]. - Mr. Bezjak has over 20 years of experience in the medical device industry, having previously served as President of the Americas division at Zimmer Biomet [2][4]. - His leadership experience includes driving commercial transformations and achieving consistent revenue and operating income growth [2][4]. Group 2: Leadership Perspective - Aldo Denti, EVP and Chief Commercial Officer, emphasized that Bezjak's appointment is crucial for executing the company's growth strategy and enhancing customer focus [3]. - Bezjak's background in Orthopedics aligns with Dentsply Sirona's goals of improving customer engagement and field execution [3]. Group 3: Background of Mark R. Bezjak - Mr. Bezjak has held multiple senior leadership roles at Zimmer Biomet, focusing on commercial transformation and financial management [4]. - He has a Bachelor of Science in Marketing from Virginia Tech and an MBA from the University of Richmond [4]. Group 4: Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, with a history of over a century in the dental industry [5]. - The company offers a comprehensive range of dental and oral health products, aiming to advance patient care and improve dental services [5].

Company Overview - DENTSPLY SIRONA Inc. (NASDAQ:XRAY) specializes in dental equipment and digital tools, including imaging systems, scanners, 3D printing solutions, and everyday dental instruments and consumables [2] - The company also provides clear aligners, implant and restorative products, treatment-planning software, and healthcare products such as catheters and irrigation systems [2] Investment Insights - Jim Cramer highlighted DENTSPLY SIRONA as a stock that has transitioned from being a high-growth company to one that is currently undervalued, suggesting it represents a buying opportunity [1] - Heartland Advisors noted that management has been working on a turnaround strategy for over two years, although these efforts have not yet been reflected in the stock price [2] Market Position - The company is recognized as one of the world's leading suppliers of dental equipment and supplies, indicating a strong market presence [2] - Despite the potential of DENTSPLY SIRONA as an investment, some analysts believe that certain AI stocks may offer greater upside potential with less downside risk [3]

Core Insights - Dentsply Sirona will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, where CEO Dan Scavilla will discuss the company's Connected Dentistry portfolio, market trends, and growth strategy [1] Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies globally, with over a century of innovation in the dental industry [3] - The company develops, manufactures, and markets a comprehensive range of dental and oral health products, as well as consumable medical devices under a strong portfolio of brands [3] - Dentsply Sirona's innovative products aim to provide high-quality, effective, and connected solutions to enhance patient care and improve dental safety [3] - The company is headquartered in Charlotte, North Carolina, and its shares are listed on Nasdaq under the symbol XRAY [3]

Core Insights - Investors are increasingly turning to dividend-yielding stocks during market turbulence, favoring companies with high free cash flows that offer substantial dividends [1] Company Summaries Pfizer Inc (NYSE:PFE) - Dividend Yield: 6.67% - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and reduced the price target from $33 to $32 as of October 10, 2025, with an accuracy rate of 67% [7] - B of A Securities analyst Tim Anderson kept a Neutral rating and increased the price target from $28 to $30 on October 3, 2025, with an accuracy rate of 66% [7] - Recent News: Pfizer completed the acquisition of Metsera, Inc. on November 13 [7] DENTSPLY SIRONA Inc (NASDAQ:XRAY) - Dividend Yield: 5.84% - William Blair analyst Brandon Vazquez downgraded the stock from Outperform to Market Perform on November 7, 2025, with an accuracy rate of 68% [7] - UBS analyst Kevin Caliendo maintained a Buy rating but cut the price target from $24 to $23 on October 28, 2025, with an accuracy rate of 67% [7] - Recent News: Dentsply Sirona reported weaker-than-expected third-quarter earnings and lowered guidance on November 6 [7] Viatris Inc (NASDAQ:VTRS) - Dividend Yield: 4.40% - Goldman Sachs analyst Matt Dellatorre initiated coverage with a Neutral rating and a price target of $10 on June 6, 2025, with an accuracy rate of 68% [7] - Piper Sandler analyst David Amsellem reiterated a Neutral rating and reduced the price target from $14 to $10 on March 5, 2025, with an accuracy rate of 78% [7] - Recent News: Viatris reported better-than-expected quarterly earnings on November 6 [7]

Core Viewpoint - The article discusses three high-yielding dividend stocks in the healthcare sector, emphasizing that high dividend yields should not be the sole focus for investors, as they may indicate value traps rather than genuine investment opportunities [1][2]. Bristol Myers Squibb (BMY) - Bristol Myers Squibb has a current price of $49.08 and a market cap of $99 billion, with a forward dividend yield of approximately 5.3% [3][4]. - The stock is trading at 7.5 times forward earnings estimates, which may suggest it is undervalued, but the company has faced challenges due to competition from generics for its blockbuster drugs [4][5]. - Despite these challenges, the company reported a 3% increase in sales last quarter and adjusted earnings of $1.63 per share, exceeding analysts' estimates [5][6]. - The company has consistently raised its dividend since 2010, providing steady returns to investors [6]. Pfizer (PFE) - Pfizer's current price is $25.87, with a market cap of $145 billion and a forward dividend yield of 7% [7][8]. - The stock is valued at around 9 times forward earnings, reflecting investor concerns over its growth prospects [8]. - Pfizer has a strong history of dividend growth, having increased its payouts for 16 consecutive years [8]. - The company recently acquired Metsera for $10 billion, which could address its patent cliff issue and enhance earnings growth if successful [9][10]. Dentsply Sirona (XRAY) - Dentsply Sirona trades at approximately $10.84, with a market cap of $2 billion and a forward dividend yield of around 5.7% [11][12]. - The stock is currently valued at about 6.5 times forward earnings, indicating a low valuation despite being a leading supplier of dental supplies and medical devices [11][12]. - The company is facing declining sales across all business segments and has experienced recent leadership changes, which may contribute to its low stock price [12][13]. - If the new CEO successfully implements a "return-to-growth action plan," the stock's valuation could improve while investors benefit from the high dividend in the interim [13].